InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Goldberg Mark Alan, Director. Director active across 2 companies, notably Glycomimetics INC. In total, 6 reports have been published. Total volume traded: €270k. The latest transaction was filed on 21 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
02,600 shares0
Common Stock
SEC:0001415889-22-007131:0·
€269,8805,000 shares@ €53.976100.0% of flow
Common Stock
SEC:0001415889-22-002653:0·
Ideal exit: 28 Nov 2022 (T+270)
02,250 shares0
Common Stock
SEC:0001179110-21-006420·
02,250 shares0
Common Stock
SEC:0001179110-21-006420:0·
05,250 shares0
Common Stock
SEC:0001209191-21-036378·
05,250 shares0
Common Stock
SEC:0001209191-21-036378:0·
6 of 6 declarations
About Goldberg Mark Alan
Mark Alan Goldberg is a Board Member at GlycoMimetics Inc. and Blueprint Medicines Corp. He contributes to the governance of both companies, bringing his expertise in the biopharmaceutical sector. His role is essential in guiding GlycoMimetics and Blueprint in their growth and innovation strategies.
